Analytical Data
-
基因名
Coagulation factor IX/F9
-
简介
Factor IX (F9) is a vitamin K-dependent plasma protein that plays a critical role in the intrinsic pathway of coagulation. Factor IX coordinates the conversion of factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa. Coagulation factor IX/F9 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor IX/F9 protein, expressed by HEK293 , with C-6*His labeled tag.
- Application
-
生物活性
1. Measured by its ability to cleave the fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2. Read at excitation and emission wavelengths of 320 nm and 405 nm (top read).The specific activity is >110.07 pmol/min/μg, as measured under the described conditions. 2. Measured by its ability to cleave the peptide substrate Z-D-Arg-Gly-Arg-pNA and the specific activity is >20 pmol/min/ug. (Activation description: The proenzyme needs to be activated by Thermolysin for an activated form.)
-
别名
rHuCoagulation factor IX/F9, His; F9; Coagulation factor IX; Christmas factor; Plasma thromboplastin component; Coagulation factor IXa light chain; Coagulation factor IXa heavy chain
-
种属
Human
-
表达系统
HEK293
-
标签
C-6*His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P00740-1
-
表达区间
T29-T461
-
氨基酸序列
TVFLDHENANKILNRPKRYNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT
-
蛋白长度
Full Length of Mature Protein (with Propeptide)
-
分子量
60-90 kDa, due to glycosylation.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Coagulation factor IX (F9) is a crucial protein in the blood coagulation cascade, primarily responsible for the activation of factor X, which ultimately leads to thrombin formation and fibrin clot development. Deficiency or dysfunction of factor IX results in Hemophilia B, a genetic bleeding disorder that affects predominantly males and leads to spontaneous or prolonged bleeding episodes. Advances in the understanding of the molecular mechanisms underlying Hemophilia B have paved the way for the development of recombinant factor IX products, which provide a therapeutic option for patients. These recombinant proteins are synthesized using recombinant DNA technology, allowing for the production of highly purified and safe products that can replace the deficient coagulation factor in affected individuals. Research has focused on improving the pharmacokinetic properties of these proteins to enhance their efficacy and reduce the frequency of administration. Additionally, studies are investigating the use of gene therapy as a potential long-term solution for Hemophilia B, offering the promise of sustained factor IX production within patients. The ongoing innovations in recombinant factor IX therapeutics reflect the need for more effective and accessible treatments for individuals living with this condition, ultimately aiming to improve their quality of life and outcomes in clinical settings.
